ANTI-CD20/ANTI-CD3 BISPECIFIC IGM ANTIBODY IGM2323

Name: ANTI-CD20/ANTI-CD3 BISPECIFIC IGM ANTIBODY IGM2323 in Non-Hodgkin Lymphoma
Creator: Floatz
License: https://terminal.floatz.ai/terms

Non-Hodgkin Lymphoma

monoclonal_antibodyDormant

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

411 Active assets in the Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
CYCLOSPORIN A Memorial Sloan Kettering Cancer Center	Phase 3	BBB
PEGASPARGASE Ciusss de L'Est de l'Île de Montréal	Phase 4	BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Mwanasha Merrill, MD	Phase 3	BBB
Inno-206 National Cancer Institute (NCI)	Phase 4	BBB
Entecavir Fudan University	Phase 4	BBB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →